India, Feb. 18 -- Bellerophon Therapeutics, Inc. (BLPH) shares are currently gaining 95% on Tuesday morning after the clinical-stage biotherapeutics company reported positive results from its study for treatment of pulmonary hypertension. BLPH is currently trading at $6.70, up $3.27 or 95.34%, on the Nasdaq, on a volume of 4.7 million shares, compared to its average volume of 53 thousand. Bellerophon Tuesday announced positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis.
The results showed that acute treatment with INOpulse provided statistically and clinically significant improvements in hemodyna...